Consolidation in the pharmaceutical industry
Written by ForeignExchange Translations on Saturday, March 14, 2009Yesterday, the New York Times ran a piece about J&J's possible reactions to the pending Merck/Schering-Plough merger. The article contained an interesting look at mergers and acquisitions in the pharmaceutical industry over the past 15 or so years:
For medical translation service providers, this is both good and bad news: On the one hand, mergers provide work through rebranding, integration, and legal efforts. On the other hand, consolidation means that overall, the net words translated get reduced. So it's no wonder that there is a lot of hand-wringing in the translation business anytime a new pharma merger is announced.
Like this post? Subscribe to Medical Translation Insight via email or RSS!
2 Comments:
-
March 15, 2009 12:06 PM
This is only bad - bad for the industry and bad for us translators.August 29, 2011 9:58 AMAnd even more important - bad news for the patients as it slows down true innovation.
Subscribe to:
Post Comments (Atom)
